

- Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH 3rd, Hazzard WR (1984): Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. *Biochim Biophys Acta* 795:293-296.
- Albers JJ, Kennedy H, Marcovina SM (1996): Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data. *J Lipid Res* 37:192-196.
- Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C (1994): Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. *Atherosclerosis* 106: 9-19.
- Armstrong VW, Walli AK, Seidel D (1985): Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). *J Lipid Res* 11:1314-1323.
- Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D (1990): Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. *J Lipid Res* 31: 429-441.
- Aveynier E, Peronnon C, Valenti K, Laporte F (1998): Apolipoprotein (a) isoform size determination. Value and limits of high resolution phenotyping by agarose gel electrophoresis. *Ann Biol Clin* 56: 73-78.
- Bas Leerink C, Duif PF, Gimpel JA, Kortlandt W, Bouma BN, van Rijn HJ (1992): Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation *Thromb Haemost* 68: 185-188.
- Bas Leerink CB, Duif PFCCM, Verhoeven N, Hackeng CM, Leus FR, Prins J, Bouma BN, Vanrijn HJM (1994): Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin- modified des-AA-fibrinogen. *Fibrinolysis* 8: 214-220.
- Barbagallo CM, Averna MR, Sparacino V, Galione A, Caputo F, Scafidi V, Amato S, Mancino C, Cefalu AB, Notarbartolo A (1993): Lipoprotein (a) levels in end-stage renal failure and renal transplantation. *Nephron* 64:560-564.
- Bard JM, Delattre-Lestavel S, Clavey V, Pont P, Derudas B, Parra HJ, Fruchart JC (1992): Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E. *Biochim Biophys Acta* 127: 124-130.
- Bdeir K, Cane W, Canziani G, Chaiken I, Weisel J, Koschinsky ML, Lawn RM, Bannerman PG, Sachais BS, Kuo A, Hancock MA, Tomaszewski J, Raghunath PN, Ganz T, Higazi AA, Cines DB (1999): Defensin promotes the binding of lipoprotein(a) to vascular matrix. *Blood* 94: 2007-2019.
- Becker L, McLeod RS, Marcovina SM, Yao Z, Koschinsky ML (2001): Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a). *J Biol Chem* 276:36155-36162.
- Berg K (1963): A new serum system type in man. The Lp-system. *Acta Pathol Microbiol Scand* 59: 369-389.
- Berg K, Roald B, Sande H (1994): High Lp(a) lipoprotein level in maternal serum may interfere with placental circulation and cause fetal growth retardation. *Clin Genet* 46: 52-56.

- Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM (1988): Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. *Arteriosclerosis* 8: 851-857.
- Boffelli D, Zajchowski DA, Yang Z, Lawn RM (1999): Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. *J Biol Chem* 274:15569-15574.
- Boerwinkle E, Menzel HJ, Kraft HG, Utermann G (1989): Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. *Hum Genet* 82:73-78.
- Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH (1992): Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. *J Clin Invest* 90:52-60.
- Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM (1997): Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. *J Clin Invest* 100: 558-564.
- Borba EF, Santos RD, Bonfa E, Vinagre CG, Pileggi FJ, Cossermelli W, Maranhao RC (1994): Lipoprotein(a) levels in systemic lupus erythematosus. *J Rheumatol* 21:220-223.
- Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP (1994): A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. *Circulation* 90: 1688-1695.
- Bowden JF, Pritchard PH, Hill JS, Frohlich JJ (1994): Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia. *Arterioscler Thromb* 4:1561-1568.
- Buechler C, Ullrich H, Ritter M, Porsch-Oezcuereomez M, Lackner KJ, Barlage S, Friedrich SO, Kostner GM, Schmitz G (2001): Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. *Blood* 97: 981-986.
- Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR (1998): Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. *J Am Coll Cardiol* 31: 519-525.
- Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ Jr, Simari RD (2001). Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. *Blood* 98: 2980-2987.
- Cheesman EJ, Sharp RJ, Zlot CH, Liu CY, Taylor S, Marcovina SM, Young SG, McCormick SP (2000): An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). *J Biol Chem* 275:28195-28200.
- Cremer P, Nagel D, Labrot B, Mann H, Mueche R, Elster H, Seidel D (1994): Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). *Eur J Clin Invest* 24: 444-453.
- Csaszar A, Karadi I, Juhasz E, Romics L (1995): High lipoprotein(a) levels with predominance of high molecular weight apo(a) isoforms in patients with pulmonary embolism. *Eur J Clin Invest* 25: 368-370.

- Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM (1990): Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. *Proc Natl Acad Sci U S A* 87: 5134-5138.
- Dahlen G, Berg K, Frick MH (1976): Lp(a) lipoprotein/pre-beta -1 lipoprotein serum lipids and atherosclerotic disease. *Clin Genet* 9: 558-566.
- Dahlen G, Ericson C, Berg K (1978): In vitro studies of the interaction of isolated Lp(a) lipoprotein and other serum lipoproteins with glycosaminoglycans. *Clin Genet* 14: 36-42.
- de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW (1993): Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. *J Clin Endocrinol Metab* 76:121-126.
- de la Peña A, Izaguirre R, Anglés-Cano E Lipoprotein Lp(a) and atherotrombotic disease. *Arch. Med Research* 31; 353-359
- de Rijke YB, Jurgens G, Hessels EM, Hermann A, van Berkel TJ (1992): In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats. *J Lipid Res* 33: 1315-1325.
- Dudani AK, Ganz PR (1996): Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). *Br J Haematol* 95: 168-178.
- Edelstein C, Italia JA, Klezovitch O, Scanu AM (1996): Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]. *J Lipid Res* 37:1786-1801.
- Edelstein C, Italia JA, Klezovitch O, Scanu AM (1997): Metalloproteinase-2 cleaves lipoprotein(a) and apolipoprotein(a) in the linker region between kringles IV-4 and IV-5 (Abstr.) *Circulation* 96(suppl): 111.
- Edelstein C, Italia JA, Scanu AM (1997): Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. *J Biol Chem* 272: 11079-11087.
- Edelstein C, Shapiro SD, Klezovitch O, Scanu AM (1999): Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. *J Biol Chem* 274: 10019-10023.
- Ehnholm C, Garoff H, Simons K, Aro H (1971): Purification and quantitation of the human plasma lipoprotein carrying the Lp(a) antigen. *Biochim Biophys Acta* 236: 431-439.
- Ehnholm C, Garoff H, Renkonen O, Simons K (1972): Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. *Biochemistry* 11: 3229-3232.
- Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL (1991): Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. *J Biol Chem* 266: 2459-2465.
- Ernst A, Helmhold M, Brunner C, Petho-Schramm A, Armstrong VW, Muller HJ (1995): Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). *J Biol Chem* 270: 6227-34.

- Ezratty A, Simon DI, Loscalzo J (1993): Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. *Biochemistry* 32: 4628-4633.
- Fless GM, Rolih CA, Scanu AM (1984): Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. *J Biol Chem* 259: 11470-11478.
- Fless GM, ZumMallen ME, Scanu AM. (1985): Isolation of apolipoprotein(a) from lipoprotein(a). *J Lipid Res* 26: 1224-1229.
- Fless GM, ZumMallen ME, Scanu AM (1986): Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a). *J Biol Chem* 261: 8712-8718.
- Fless GM, Santiago JY (1997): Molecular weight determination of lipoprotein(a) [Lp(a)] in solutions containing either NaBr or D2O: relevance to the number of apolipoprotein(a) subunits in Lp(a). *Biochemistry* 36:233-238.
- Frank SL, Klisak I, Sparkes RS, Mohandas T, Tomlinson JE, McLean JW, Lawn RM, Lusis AJ (1988): The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. *Hum Genet* 79:352-356.
- Frank S, Durovic S, Kostner K, Kostner GM (1995): Inhibitors for the in vitro assembly of Lp(a). *Arterioscler Thromb Vasc Biol* 15:1774-1780.
- Fu L, Jamieson DG, Usher DC, Lavi E (2001): Gene expression of apolipoprotein(a) within the wall of human aorta and carotid arteries. *Atherosclerosis* 158: 303-311.
- Gabel B, Yao Z, McLeod RS, Young SG, Koschinsky ML (1994): Carboxyl-terminal truncation of apolipoproteinB-100 inhibits lipoprotein(a) particle formation. *FEBS Lett* 350:77-81.
- Gabel BR, McLeod RS, Yao Z, Koschinsky ML (1998): Sequences within the amino terminus of ApoB100 mediate its noncovalent association with apo(a). *Arterioscler Thromb Vasc Biol* 18:1738-1744.
- Galis ZS, Sukhova GK, Lark MW, Libby P (1994): Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. *J Clin Invest* 94: 2493-2503.
- Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH (1983): *J Biol Chem* 258: 4582-4589.
- Gaubatz JW, Chari MV, Nava ML, Guyton JR, Morrisett JD (1987): Isolation and characterization of the two major apoproteins in human lipoprotein [a]. *J Lipid Res* 28: 69-79.
- Gaw A, Hobbs HH (1994): Molecular genetics of lipoprotein (a): new pieces to the puzzle. *Curr Opin Lipidol* 5:149-155.
- Gonbert S, Saint-Jore B, Giral P, Doucet C, Chapman J, Thillet J (2001): Molecular analysis of apo(a) fragmentation in polygenic hypercholesterolemia: characterization of a new plasma fragment pattern. : *Arterioscler Thromb Vasc Biol* 21:1353-1358.
- Gonzalez-Gronow M, Edelberg JM, Pizzo SV (1989): Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. *Biochemistry* 28: 2374-2377.
- Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM (1993): Proliferation of human smooth muscle cells promoted by lipoprotein(a). *Science* 260: 1655-1658.

- Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC (1994): Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. *Nature* 370: 460-462.
- Grainger DJ Metcalfe JC. Transforming growth factor-beta: the key to understanding lipoprotein(a)? *Current Opinion in Lipidol* 6: 81-85.
- Gries A, Gries M, Wurm H, Kenner T, Ijsseldijk M, Sixma JJ, Kostner GM (1996): Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. *Arterioscler Thromb Vasc Biol* 16: 648-655.
- Guevara J Jr, Knapp RD, Honda S, Northrup SR, Morrisett JD (1992): A structural assessment of the apo[a] protein of human lipoprotein[a]. *Proteins* 12:188-199.
- Haberland ME, Fless GM, Scanu AM, Fogelman AM (1992): Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. *J Biol Chem* 267: 4143-4151.
- Hajjar KA, Gavish D, Breslow JL, Nachman RL (1989): Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. *Nature* 339: 303-305.
- Handa V, ul-Hussain M, Pati N, Pati U (2002): Multiple liver-specific factors bind to a 64-bp element and activate apo(a) gene. *Biochem Biophys Res Commun* 292: 243-249.
- Haque NS, Zhang X, French DL, Li J, Poon M, Fallon JT, Gabel BR, Taubman MB, Koschinsky M, Harpel PC (2000): CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. *Circulation* 102: 786-792.
- Harpel PC, Chang VT, Borth W (1992): Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. *Proc Natl Acad Sci U S A* 89:10193-10197.
- Harvie NR, Schultz JS (1970): Studies of Lp-lipoprotein as a quantitative trait. *Proc Natl Acad Sci USA* 66: 99-103.
- Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, Armstrong VW (1991): Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation. *J Lipid Res* 32:1919-1928.
- Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E (1993): Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? *Blood* 82: 392-397.
- Hervio L, Girard-Globa A, Durlach V, Angles-Cano E (1996): The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. *Eur J Clin Invest* 26: 411-417.
- Hoover-Plow JL, Boonmark N, Skocir P, Lawn R, Plow EF (1996) : A quantitative immunoassay for the lysine-binding function of lipoprotein(a). Application to recombinant apo(a) and lipoprotein(a) in plasma. *Arterioscler Thromb Vasc Biol* 16: 656-664.
- Hoover-Plow J, Khaitan A, Fless GM (1998): Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. *Thromb Haemost* 79: 640-648.

- Huby T, Schroder W, Doucet C, Chapman J, Thillet J (1995): Characterization of the N-terminal and C-terminal domains of human apolipoprotein(a): relevance to fibrin binding. *Biochemistry* 34: 7385-7393.
- Huby T, Datchet C, Lawn RM, Wickings J, Chapman MJ, Thillet J (2001): Functional analysis of the chimpanzee and human apo(a) promoter sequences: identification of sequence variations responsible for elevated transcriptional activity in chimpanzee. *J Biol Chem* 276:22209-22214.
- Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM (1997): Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. *J Clin Invest* 100: 1493-1500.
- Hurt-Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg E, Johansen B (1997): Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. *Arterioscler Thromb Vasc Biol* 17: 300-309.
- Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G (1997): Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. *Arterioscler Thromb Vasc Biol* 17: 1011-1017.
- Ichinose A (1992): Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. *Biochemistry* 31:3113-3118.
- Ichinose A, Kuriyama M (1995): Detection of polymorphisms in the 5'-flanking region of the gene for apolipoprotein(a). *Biochem Biophys Res Commun* 209:372-378.
- Ioka T, Tasaki H, Yashiro A, Yamashita K, Ozumi K, Tsutsui M, Kouzuma R, Okazaki M, Nakashima Y (2001): Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. *Circ J* 66: 267-271.
- Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK (1991): Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. *Atherosclerosis* 89: 59-67.
- Joven J, Simo JM, Vilella E, Camps J, Espinel E, Villabona C. (1995) Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. *Clin Chem* 41:908-13.
- Joven J, Vilella E. (1991). Serum levels of lipoprotein(a) in patients with well-controlled non-insulin-dependent diabetes mellitus. *JAMA* 265:1113-1114.
- Jurgens G, Chen Q, Esterbauer H, Mair S, Ledinski G, Dinges HP (1993): Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apoprotein(a). *Arterioscler Thromb* 13: 1689-1699.
- Kanno H, Saito E, Fujioka T, Yasugi T (1992): Lipoprotein(a) levels in the nephrotic syndrome. *Intern Med* 31:1004-1008.
- Karadi I, Kostner GM, Gries A, Nimpf J, Romics L, Malle E. (1988). Lipoprotein (a) and plasminogen are immunochemically related. *Biochim Biophys Acta* 960:91-97,
- Karadi I, Romics L, Palos G, Doman J, Kaszas I, Hesz A, Kostner GM (1989): Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. *Clin Chem* 35: 2121-2123.

- Keesler GA, Gabel BR, Devlin CM, Koschinsky ML, Tabas I (1996): The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). *J Biol Chem* 271: 32096-32104.
- Klezovitch O, Edelstein C, Scanu AM (1996): Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV-10: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes. *J Clin Invest* 98: 185-1891.
- Klezovitch O, Edelstein C, Zhu L, Scanu AM (1998): Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin. Implications for the retention of lipoprotein(a) in atherosclerotic lesions. *J Biol Chem* 273: Buechler 23856-23865.
- Kochl S, Fresser F, Lobentanz E, Baier G, Utermann G (1997): Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain. *Blood* 90: 1482-1489.
- Koschinsky ML, Beisiegel U, Henne-Bruns D, Eaton DL, Lawn RM (1990): Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. *Biochemistry* 29: 640-644.
- Koschinsky ML, Cote GP, Gabel B, van der Hoek YY (1993): Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. *J Biol Chem* 268:19819-19825.
- Kostner GM, Avogaro O, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB (1981): *Atherosclerosis* 38: 51-61.
- Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL (1989): HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. *Circulation* 80:1313-1319.
- Kostner GM, Grillhofer HK (1991): Lipoprotein(a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts. *J Biol Chem* 266:21287-21292.
- Kostner GM (1993): Interaction of Lp(a) and of apo(a) with liver cells. *Arterioscler Thromb* 13:1101-1109.
- Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner GM (1996): Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. *Arterioscler Thromb Vasc Biol* 16:905-911.
- Kostner GM, Wo X, Frank S, Kostner K, Zimmermann R, Steyrer E (1997): Metabolism of Lp(a): assembly and excretion. *Clin Genet* 52:347-354.
- Kraft HG, Menzel HJ, Hoppichler F, Vogel W, Utermann G (1989): Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. *J Clin Invest* 83:137-142.
- Kraft HG, Sandholzer C, Menzel HJ, Utermann G (1992): Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma. *Arterioscler Thromb* 2:302-306.
- Kraft HG, Kochl S, Menzel HJ, Sandholzer C, Utermann G (1992): The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. *Hum Genet* 90:220-230.
- Kraft HG, Lingenhel A, Pang RW, Delport R, Trommsdorff M, Vermaak H, Janus ED, Utermann G (1996): Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and

- African populations: the distribution of null alleles is non-random. *Eur J Hum Genet* 4: 74-87.
- Kraft HG, Windegger M, Menzel HJ, Utermann G (1998): Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. *Hum Mol Genet* 7:257-264.
- Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G (2000): Lipoprotein(a) in homozygous familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol* 20:522-528.
- Krempler F, Kostner G, Bolzano K, Sandhofer F (1979): Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B. *Biochim Biophys Acta*. 575:63-70.
- Krempler F, Kostner GM, Bolzano K, Sandhofer F (1980): Turnover of lipoprotein (a) in man. *J Clin Invest* 65:1483-1490.
- Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H (1996): Lipoprotein(a) in health and disease. *Crit Rev Clin Lab Sci* 33: 495-543.
- Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G.(1996). Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. *Arterioscler Thromb Vasc Biol* 16:1568-1572.
- Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J (1999): Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. *Circulation* 100: 1154-1160.
- Kusumi Y, Scanu AM, McGill HC, Wissler RW (1993): Atherosclerosis in a rhesus monkey with genetic hypercholesterolemia and elevated plasma Lp(a). *Atherosclerosis* 99: 165-174.
- Lawn RM, Boonmark NW, Schwartz K, Lindahl GE, Wade DP, Byrne CD, Fong KJ, Meer K, Patthy L (1995). The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). *J Biol Chem* 270 : 24004-24009.
- Lawn RM, Schwartz K, Patthy L (1997). Convergent evolution of apolipoprotein(a) in primates and hedgehog. *Proc Natl Acad Sci U S A* 94: 11992-11997.
- *Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH (1991): Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. *J Clin Invest* 87:2153-2161.
- Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY (1993): The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. *Clin Chim Acta* 223:73-82.
- Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, Plow EF (1994): Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. *Arterioscler Thromb* 14: 438-442.
- Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM, Gianturco SH, Bradley WA, Fless GM, Booyse FM (1997): Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. *Arterioscler Thromb Vasc Biol* 17:3215-3223.
- Lindahl G, Gersdorf E, Menzel HJ, Seed M, Humphries S, Utermann G (1990): Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene. *Hum Genet* 84: 563-567.

- Lingenhel A, Kraft HG, Kotze M, Peeters AV, Kronenberg F, Kruse R, Utermann G (1998). Concentrations of the atherogenic Lp(a) are elevated in FH. *Eur J Hum Genet* 6: 50-60.
- Lippi G, Braga V, Adami S, Guidi G (1998): Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. *Clin Chim Acta* 27: 79-87.
- Lippi G, Veraldi GF, Dorucci V, Dusi R, Ruzzenente O, Brentegani C, Guidi G, Cordiano C (1998): Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. *Scand J Clin Lab Invest*; 58: 497-504.
- Lippi G, Guidi G (1999): Biochemical risk factors and patient's outcome: the case of lipoprotein(a). *Clin Chim Acta* 280: 59-71.
- Lippi G, Guidi G (2000): Lipoprotein(a) from ancestral benefit to modern pathogen?. *Q J Med* 93: 75-84
- LoGrasso PV, Cornell-Kennon S, Boettcher BR (1994): Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37. *J Biol Chem* 269 : 21820-21827.
- Loscalzo J, Weinfeld M, Fless GM, Scanu AM (1990): Lipoprotein(a), fibrin binding, and plasminogen activation. *Arteriosclerosis* 10: 240-245.
- Lundstam U, Hurt-Camejo E, Olsson G, Sartipy P, Camejo G, Wiklund O (1999): Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix. *Arterioscler Thromb Vasc Biol* 19: 1162-1167.
- Magnaghi P, Citterio E, Magaretti N, Acquati F, Ottolenghi S, Taramelli R (1994): Molecular characterisation of the human apo(a)-plasminogen gene family clustered on the telomeric region of chromosome 6 (6q26-27). *Hum Mol Genet* 3:437-442.
- Magnusson S, Peterson T.E, Sottrup-Jensen, Claeys H (1975): Complete primary structure of prothrombin. Isolation structure, and reactivity of ten carboxylated glutamic acid residues and regulation of prothrombin activation by thrombin. *Proteases and biological control*. Reich E., Rifkin D.B. , Shaw E. Editors. Cold Spring Harbor Laboratories. Cold Spring Harbor. NY 123-149.
- Marcovina SM, Zhang ZH, Gaur VP, Albers JJ (1993): Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites. *Biochem Biophys Res Commun* 191:1192-1196.
- Marcovina SM, Hobbs HH, Albers JJ (1996): Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. *Clin Chem* 42: 436-439.
- Martinez ML, Vega L, Mora A, Andreu L, Molina E (1993): Lipoproteína (a). *Qim Clin* 12: 414-421.
- McCance SG, Menhart N, Castellino FJ (1994): Amino acid residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands. *J Biol Chem* 269:32405-32410.
- McCormick SP, Ng JK, Cham CM, Taylor S, Marcovina SM, Segrest JP, Hammer RE, Young SG (1997): Transgenic mice expressing human ApoB95 and ApoB97. Evidence that sequences within the carboxyl-terminal portion of human apoB100 are important for the assembly of lipoprotein. *J Biol Chem* 272: 23616-23622.

- McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM (1987): cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature* 330: 132-137.
- Miles LA, Fless GM, Scanu AM, Baynham P, Sebald MT, Skocir P, Curtiss LK, Levin EG, Hoover-Plow JL, Plow EF (1995): Interaction of Lp(a) with plasminogen binding sites on cells. *Thromb Haemost* 73: 458-465.
- Mooser V, Mancini FP, Bopp S, Petho-Schramm A, Guerra R, Boerwinkle E, Muller HJ, Hobbs HH (1995): Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. *Hum Mol Genet* 4:173-181.
- Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH (1996): Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). *J Clin Invest* 97:858-864.
- Mooser V, Marcovina SM, White AL, Hobbs HH. (1996). Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. *J Clin Invest* 98:2414-2424.
- Mooser V, Scheer D, Marcovina SM, Wang J, Guerra R, Cohen J, Hobbs HH (1997): The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans. *Am J Hum Genet* 61:402-417.
- Mooser V, Berger MM, Tappy L, Cayeux C, Marcovina SM, Darioli R, Nicod P, Chiolero R (2000): Major reduction in plasma Lp(a) levels during sepsis and burns. *Arterioscler Thromb Vasc Biol* 20:1137-1142.
- Naruszewicz M, Selinger E, Dufour R, Davignon J (1992): Probucol protects lipoprotein (a) against oxidative modification. *Metabolism* 41: 1225-1228.
- Ogorelkova M, Gruber A, Utermann G (1999): Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians. *Hum Mol Genet.* 8:2087-2096.
- Ogorelkova M, Kraft HG, Ehnholm C, Utermann G (2001): Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. *Hum Mol Genet* 10:815-824.
- Olivecrona H, Ericsson S, Berglund L, Angelin B (1993): Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment. *BMJ* 306:1726-1727.
- Olivecrona H, Johansson AG, Lindh E, Ljunghall S, Berglund L, Angelin B (1995): Hormonal regulation of serum lipoprotein(a) levels. Contrasting effects of growth hormone and insulin-like growth factor-I. *Arterioscler Thromb Vasc Biol* 15:847-849.
- O'Reilly MS (1997): Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. *EXS* 79: 273-294.
- Pati U, Pati N (2000): Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. *Mol Genet Metab* 71:87-92.
- Pay S, Ozcan N, Tokgozoglul SL (1997): Elevated Lp(a) is the most frequent familial lipoprotein disorder leading to premature myocardial infarction in a country with low cholesterol levels. *Int J Cardiol* 60: 301-315.
- Pepin JM, O'Neil JA, Hoff HF (1991): Quantification of apo[a] and apoB in human atherosclerotic lesions. *J Lipid Res* 32: 317-327.

- Perombelon YF, Soutar AK, Knight BL (1994): Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. *J Clin Invest* 93:1481-1492.
- Pillarsetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ (1997): Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. *J Clin Invest* 100: 867-874.
- Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC (1997): Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. *Circulation* 96: 2514-2519.
- Prins J, Leus FR, van der Hoek YY, Kastelein JJ, Bouma BN, van Rijn HJ (1997): The identification and significance of a Thr-->Pro polymorphism in kringle IV type 8 of apolipoprotein(a). *Thromb Haemost* 77: 949-954.
- Ragab MS, Selvaraj P, Sgoutas DS (1996): Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. *Atherosclerosis* 123: 103-113.
- Rahman MN, Petrounevitch V, Jia Z, Koschinsky ML (2001): Antifibrinolytic effect of single apo(a) kringle domains: relationship to fibrinogen binding. *Protein Eng* 14: 427-438.
- Rahman MN, Becker L, Petrounevitch V, Hill BC, Jia Z, Koschinsky ML (2002): Comparative analyses of the lysine binding site properties of apolipoprotein(a) kringle IV types 7 and 10. *Biochemistry* 41: 1149-1155.
- Ramharack R, Spahr MA, Kreick JS, Sekerke CS (1996): Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. *J Lipid Res* 37:2029-2040.
- Ramharack R, Wyborski RJ, Spahr MA (1998): The apolipoprotein(a) promoter contains a retinoid response element. *Biochem Biophys Res Commun* 245:194-197.
- Ramharack R, Barkalow D, Spahr MA (1998): Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. *Arterioscler Thromb Vasc Biol* 18: 984-990.
- Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991): Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. *Ann Rheum Dis* 50:366-368.
- Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989): Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. *Arteriosclerosis* 9: 579-592.
- Rath M, Pauling L. (1990) Hypothesis: lipoprotein(a) is a surrogate for ascorbate. *Proc Natl Acad Sci U S A*. 87:6204-6207.
- Rath M, Pauling L. (1990). Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig. *Proc Natl Acad Sci U S A* 87:9388-9390.
- Ren S, Man RY, Angel A, Shen GX (1997): Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. *Atherosclerosis* 128: 1-10.
- Ridker PM, Hennekens CH, Stampfer MJ (1993): A prospective study of lipoprotein(a) and the risk of myocardial infarction. *JAMA* 270: 2195-2199.

- Rotimi CN, Cooper RS, Marcovina SM, McGee D, Owoaje E, Ladipo M (1997): Serum distribution of lipoprotein(a) in African Americans and Nigerians: potential evidence for a genotype-environmental effect. *Genet Epidemiol* 14:157-168.
- Rosby O, Berg K (2000): LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. *J Intern Med* 247: 139-152.
- Rubanyi GM, Freay AD, Lawn RM (2000): Endothelium dependent vasorelaxation in the aorta of transgenic mice expressing human apolipoprotein(a) or lipoprotein(a). *Endothelium* 7: 253-264.
- Sacks FM, McPherson R, Walsh BW (1994): Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. *Arch Intern Med* 154:1106-1110.
- Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, Horrevoets AJ, Nesheim ME, Koschinsky ML. (1997) The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. *Biochemistry* 36:10353-10363.
- Scanu AM (1988): Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. *Arch Pathol Lab Med* 112: 1045-1047.
- Scanu AM, Fless GM (1990): Lipoprotein (a). Heterogeneity and biological relevance. *J Clin Invest* 85: 1709-1715.
- Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, Hoover-Plow JL, Brunck T, Plow EF [1993]: Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37). *J Clin Invest* 91:283-291.
- Scanu AM, Pfaffinger D, Lee JC, Hinman J.A (1994): Single point mutation (Trp72-->Arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). *Biochim Biophys Acta* 1227:41-45.
- Scanu AM, Edelstein C (1995): Kringle-dependent structural and functional polymorphism of apolipoprotein (a). *Biochim Biophys Acta* 1256: 1-12.
- Scanu AM, Atzeni MM, Edelstein C, Tonolo G, Maioli M, Klezovitch O (1997): Lipoprotein(a): identification of subjects with a superbinding capacity for fibrinogen. *Clin Genet* 52: 367-370.
- Scanu AM (1998): Atherothrombogenicity of lipoprotein(a): the debate. *Am J Cardiol* 82: 26Q-33Q.
- Scanu AM (2001): The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. *Curr Cardiol Rep* 3: 385-390.
- Scholz M, Kraft HG, Lingenhel A, Delport R, Vorster EH, Bickeboller H, Utermann G (1999): Genetic control of lipoprotein(a) concentrations is different in Africans and Caucasians. *Eur J Hum Genet* 7:169-178.
- Scott J (1989): Thrombogenesis linked to atherogenesis at last?. *Nature* 341: 22-23.
- Seed M, Ayres KL, Humphries SE, Miller GJ (2001): Lipoprotein (a) as a predictor of myocardial infarction in middle-aged men. *Am J Med* 110: 22-27.
- Shapiro SD, Kobayashi DK, Ley TJ (1993): Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. *J Biol Chem* 268: 23824-23829.

- Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE (1994): Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. *J Clin Invest* 93: 50-55.
- Soulat T, Loyau S, Baudouin V, Durlach V, Gillery P, Garnotel R, Loirat C, Angles-Cano E (1999): Evidence that modifications of Lp(a) in vivo inhibit plasmin formation on fibrin--a study with individual plasmas presenting natural variations of Lp(a). *Thromb Haemost* 82: 121-127.
- Soulat T, Loyau S, Baudouin V, Maisonneuve L, Hurtaud-Roux MF, Schlegel N, Loirat C, Angles-Cano E (2000): Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: An in vitro study using plasma from children with idiopathic nephrotic syndrome. *Arterioscler Thromb Vasc Biol* 20: 575-584.
- Takahashi A, Taniguchi T, Fujioka Y, Ishikawa Y, Yokoyama M (1996): Effects of lipoprotein(a) and low density lipoprotein on growth of mitogen stimulated human umbilical vein endothelial cells. *Atherosclerosis* 120: 93-99.
- Tavola A, D'Angelo SV, Bandello F, Brancato R, Parlavecchia M, Safa O, D'Angelo A (1995): Central retinal vein and branch artery occlusion associated with inherited plasminogen deficiency and high lipoprotein(a) levels: a case report. *Thromb Res* 80: 327-331.
- Thillet J, Faucher C, Issad B, Allouache M, Chapman J, Jacobs C (1993): Lipoprotein(a) in patients treated by continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 22: 226-232.
- Tulinsky A, Park CH, Mao B, Llinas M (1988): Lysine/fibrin binding sites of kringles modeled after the structure of kringle 1 of prothrombin. *Proteins* 3: 85-96.
- Utermann G, Wiegand H (1969): Separation and characterization of a lipoprotein with antigenic activity in the Lp(a) system. *Humangenetik* 8: 39-46.
- Utermann G, Weber W (1983): Protein composition of Lp(a) lipoprotein from human plasma. *FEBS Lett* 154: 357-361.
- Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C (1987): Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. *J Clin Invest* 80: 458-465.
- Utermann G, Duba C, Menzel HJ (1988): Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. *Hum Genet* 78:47-50.
- Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E (1989): Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. *Proc Natl Acad Sci U S A* 86: 4171-4174.
- Utermann G (1989): The mysteries of lipoprotein(a). *Science* 246: 904-910.
- Utermann G (1995] Lipoprotein(a). En: Scriver CR, Beauder AL, Sly WS, Valle D eds. *Metabolic and molecular bases of inheritance disease* 7th ed. Vol 2 New York McGraw-Hill: 1887-1912.
- Valenti K, Aveyrier E, Laporte F, Hadjian AJ (1997): Evaluation of the genotyping and phenotyping approaches in the investigation of apolipoprotein (a) size polymorphism. *Clin Chim Acta* 263: 249-260.

- von Eckardstein A, Schulte H, Cullen P, Assmann G (2001): Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. *J Am Coll Cardiol* 37: 434-439.
- Wade DP, Clarke JG, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM (1993): 5' control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. *Proc Natl Acad Sci USA* 90: 1369-1373.
- Wade DP, Lindahl GE, Lawn RM (1994): Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor 1 alpha. *J Biol Chem* 269:19757-19765.
- Wade DP, Puckey LH, Knight BL, Acquati F, Mihalich A, Taramelli R (1997): Characterization of multiple enhancer regions upstream of the apolipoprotein(a) gene. *J Biol Chem* 272:30387-30399.
- Wang J, Mimuro S, Lahoud R, Trudinger B, Wang XL (1998): Elevated levels of lipoprotein(a) in women with preeclampsia. *Am J Obstet Gynecol* 178:146-149.
- Weikamp LR, Guttormsen SA, Schultz JS (1988): Linkage between the loci for the Lp(a) lipoprotein (LP) and plasminogen (PLG). *Hum Genet* 79: 80-82.
- White AL, Rainwater DL, Lanford RE (1993): Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes. *J Lipid Res* 34:509-517.
- White AL, Rainwater DL, Hixson JE, Estlack LE, Lanford RE (1994): Intracellular processing of apo(a) in primary baboon hepatocytes. *Chem Phys Lipids*: 67-68:123-133.
- Wight TN The extracellular matrix and atherosclerosis (1995): *Curr Opin Lipidol* 6: 326-334.
- Wild SH, Fortmann SP, Marcovina SM (1997): A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arterioscler Thromb Vasc Biol* 17: 239-245.
- Wright LC, Sullivan DR, Muller M, Dyne M, Tattersall MHN, Mounford CE. (1989): Elevated apolipoprotein(a) levels in cancer patients. *Int J Cancer* 3: 241-244
- Xia J, May LF, Koschinsky ML (2000): Characterization of the basis of lipoprotein [a] lysine-binding heterogeneity. *J Lipid Res* 41: 1578-1584.
- Xu XX, Tabas I (1991): Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages. *J Biol Chem* 266: 24849-24858.
- Yamada S, Morishita R, Nakamura S, Ogihara T, Kusumi Y, Sakurai I, Kubo N, Sakurabayashi I (2000): Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). *Circulation* 102: 1639-1644.
- Yang Z, Boffelli D, Boonmark N, Schwartz K, Lawn R (1998): Apolipoprotein(a) gene enhancer resides within a LINE element. *J Biol Chem* 273:891-897.
- Yano Y, Shimokawa K, Okada Y, Noma A (1997): Immunolocalization of lipoprotein(a) in wounded tissues. *J Histochem Cytochem* 45: 559-568.
- Ye Q, Rahman MN, Koschinsky ML, Jia Z (2001): High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: insights into ligand binding. *Protein Sci* 10: 1124-1129.
- Zawadzki Z, Terce F, Seman LJ, Theolis RT, Breckenridge WC, Milne RW, Marcel YL (1988): The linkage with apolipoprotein (a) in lipoprotein (a) modifies the

immunochemical and functional properties of apolipoprotein B. *Biochemistry* 27: 8474-8481

Zysow BR, Lindahl GE, Wade DP, Knight BL, Lawn RM (1995): C/T polymorphism in the 5' untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. *Arterioscler Thromb Vasc Biol* 15: 58-64.